Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

  • valentinfernandezgarcia valentinfernandezgarcia Apr 16, 2010 5:04 AM Flag

    Rintatolimod (Ampligen) update

    4/08/2010 Hemispherx Biopharma completes phase II trials in HIV infections. (source FDA).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ... do you have a link?

      Thanx!

      Best wishes!

      • 1 Reply to steelman068
      • Rintatolimod - (Update)Pipeline Drug Development History Event Date Development history
        4/8/2010 Hemispherx Biopharma completes phase II trials in HIV infections
        2/8/2010 Discontinued - Preclinical for Smallpox in USA (IV)
        12/1/2009 Hemispherx Biopharma receives complete response letter from the US FDA for rintatolimod in Chronic fatigue syndrome
        10/22/2009 Pharmacodynamics data from a preclinical study in macaque monkeys in Influenza virus infections released by Hemispherx Biopharma
        5/26/2009 The US FDA advises Hemispherx Biopharma of a possible brief delay in its action report for the NDA filing of rintatolimod for Chronic fatigue syndrome
        2/18/2009 The US FDA extends the PDUFA review date for the NDA filing of rintatolimod for Chronic fatigue syndrome
        11/18/2008 Hemispherx Biopharma enters into a research contract agreement with Lovelace Respiratory Research Institute to conduct additional preclinical studies with rintatolimod for Chronic fatigue syndrome in USA
        7/8/2008 The US FDA accepts Hemispherx Biopharma's NDA filing of rintatolimod for review in Chronic fatigue syndrome

 
HEB
0.1353-0.0007(-0.51%)May 2 4:02 PMEDT